Candel Therapeutics, Inc. (CADL) earnings
CADL earnings moved a median of +4.30% by the close. Quarterly and annual CADL reports and results, each read against the price at its own news timestamp. Back to the CADL overview →
22 measured CADL earnings events.
Where these CADL earnings landedvs 20 measured CADL earnings reactions
| Middle 50% of CADL earnings reactions | -1.47% to +7.32% |
|---|---|
| Median reaction (to close) | +4.30% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 CADL earnings events with a measured close landed between -1.47% and +7.32%; 65% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights | Press release | -0.92% | +8.76% | |
| Form 10-Q Candel Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.92% | +8.76% | |
| Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Press release | -9.34% | -2.62% | |
| Form 10-Q Candel Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -9.34% | -2.62% | |
| Form 10-K Candel Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.20% | -0.60% | |
| Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | Press release | -1.43% | — | |
| Form 10-Q Candel Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.43% | — | |
| Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | Press release | +2.28% | -1.47% | |
| Form 10-Q Candel Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +2.28% | -1.47% | |
| Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | Press release | +0.39% | +5.78% | |
| Form 10-Q Candel Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.39% | +5.78% | |
| Form 10-K Candel Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +1.88% | +9.93% | |
| Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | Press release | -2.82% | +1.18% | |
| Form 10-Q Candel Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -2.82% | +1.18% | |
| Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights | Press release | +0.00% | +4.66% | |
| Form 10-Q Candel Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +4.66% | |
| Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights | Press release | +0.20% | +7.32% | |
| Form 10-Q Candel Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.20% | +7.32% | |
| Form 10-K/A Candel Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -2.11% | +8.98% | |
| Form 10-K Candel Therapeutics, For: Dec 31 | SEC filing · Form 10-K | — | +3.95% | |
| Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights | Press release | -12.87% | -19.44% | |
| Form 10-Q Candel Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -12.87% | -19.44% |
Keep exploring
More CADL: analyst actions → · SEC filings → · CADL overview →